Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen

Completed Rolling Submission Beats Lilly’s Donanemab To US FDA

Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab. 

Retro alarm clock at 5 minutes to 12 o'clock
The clock is ticking in the competition to bring the next anti-amyloid antibody to market • Source: Shutterstock

Biogen, Inc.’s Aduhelm (aducanumab) was one of the most closely watched and worst-performing drug launches in recent memory. But as the company winds down commercialization of the anti-amyloid antibody, partner Eisai Co., Ltd. has completed a rolling biologic license application (BLA) submission to the US Food and Drug Administration for a second anti-amyloid antibody, offering hope for another potential shot at a blockbuster product for the disease.

Eisai and Biogen are seeking accelerated approval for lecanemab, despite the recent US Centers for Medicare and Medicaid Services (CMS)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.